Authors: Rosen, LS Gordon, D Kaminski, M Howell, A Belch, A Mackey, J Apffelstaedt, J Hussein, M Coleman, RE Reitsma, DJ Seaman, JJ Chen, BL Ambros, Y

Citation: Ls. Rosen et al., Zoledronic acid versus pamidronate in the treatment of skeletal metastasesin patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial, CANCER J, 7(5), 2001, pp. 377-387

Authors: Coleman, RE Seaman, JJ

Citation: Re. Coleman et Jj. Seaman, The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases, SEMIN ONCOL, 28(2), 2001, pp. 11-16

Authors: Berenson, JR Rosen, LS Howell, A Parter, L Coleman, RE Morley, W Dreicer, R Kuross, SA Lipton, A Seaman, JJ

Citation: Jr. Berenson et al., Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study, CANCER, 91(7), 2001, pp. 1191-1200

Authors: Lipton, A Theriault, RL Hortobagyi, GN Simeone, J Knight, RD Mellars, K Reitsma, DJ Heffernan, M Seaman, JJ

Citation: A. Lipton et al., Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases - Long term follow-up of two randomized, placebo-controlled trials, CANCER, 88(5), 2000, pp. 1082-1090

Authors: Theriault, RL Lipton, A Hortobagyi, GN Leff, R Gluck, S Stewart, JF Costello, S Kennedy, I Simeone, J Seaman, JJ Knight, RD Mellars, K Heffernan, M Reitsma, DJ

Citation: Rl. Theriault et al., Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial, J CL ONCOL, 17(3), 1999, pp. 846-854